Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEPANC-1: IMM-101 plus stereotactic radiotherapy in limited metastatic pancreatic cancer
2024-514598-23-00Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMM-101 in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Erasmus MC. Primary endpoints: Safety and toxicity of IMM-101 and SBRT and Efficacy of IMM-101 plus SBRT. Started Aug 2024; status: completed.
02
Drugs
IMM-101
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-514598-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514598-23-00.